.webp)
Revolutionizing ADCs
for Safer Cancer Therapies
At BioLoomics, we harness directed evolution to improve antibody-drug conjugate internalization and trafficking
Our Science
We Have a Unique Process To Discover Antibody-Peptide Chimeras That Traffic to Specific Subcellular Organelles
Learn More
Our Technology
We leverage activity-guided antibody library screening through Synthetic Biology, AI, Imaging, and Robotics to build a robust therapeutic pipeline of anti-cancer therapies
Learn More.webp)
About Us
Interdisciplinary pioneers driven by a common mission to create the next generation of antibody scaffolds.
We combine deep experience in synthetic biology, machine learning, and protein design to bring robust therapeutic solutions to patients with unmet needs.
Meet Our TeamLatest News
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
October 15, 2024
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Our mission is to make safer, more effective cancer therapeutics.
June 13, 2024
Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
BioLoomics’ goal is to make a degrader from an antibody in one month
June 13, 2024
Pre-Seed Extension
BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..
June 13, 2024
OEDIT Grant Award
The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...
June 13, 2024
BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform
We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...
June 13, 2024
